Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.29), $0.05 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $1 million versus the consensus estimate of $940 thousand.

Cash, cash equivalents and short-term investments as of December 31, 2017 were $100.9 million compared to $92.1 million as of December 31, 2016. The increase was primarily driven by $43.2 million in net cash proceeds received by the Company from its December 2017 public offering of common stock and $7.5 million in net cash proceeds received by the Company in July 2017 in connection with the amendment of its loan agreement with Silicon Valley Bank. These proceeds were offset by the Company’s use of cash to fund operating activities and to service principal and interest obligations under its loan agreement with Silicon Valley Bank.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.